Pipeline

Pipeline 2018-10-15T17:15:46+00:00

Our strategic focus is small molecule inhibitors that can be placed as targeted therapy for solid tumors, addressing issues of drug resistance and tumor heterogeneity. We are advancing three oncology drugs with unique mechanisms of action for the treatment of unmet cancer needs using a precision medicine approach.

ABANDONED by Indication Drugs R&D Preclinical Phase I Phase II Phase III

HRPC​
Prostate​

LP-100
Irofulven-1​

NCSLC​
Lung​

LP-300​
Tavocept​

Prostate & Ovarian​ Cancer​

LP-184​
Irofulven-2​

Mechanism of Action

Irofulven-1 is a non-hormone, non-chemotherapy, next-generation DNA Damage Repair (DDR) inhibitor.

Background

Drug was developed by MGI & EISAI.
Objective response in 12-15% prostate and ovarian cancer patients but program shelved. 30+ clinical trials and 900 patients treated. Successful out-licensing to OV in 18 months.

Mechanism of Action

Tavocept is a first-in-class selective-spectrum receptor tyrosine kinase inhibitor indicated in non-small cell lung cancer. With chemoprotective and chemosensitizing activity, Tavocept is a potential combination agent or adjuvant in front line, second line or salvage therapy in newly diagnosed, relapsed, metastatic or advanced NSCLC for overall survival enhancement and toxicity alleviation from primary chemotherapy or standard of care. Tavocept has great promise to be used synergistically with various treatment regimens including chemotherapy, targeted therapy and immunotherapy combinations by virtue of its multi-modal mechanism of action, capacity to counter multi-drug resistance, and statistically significant survival outcomes in subgroups in previous clinical trials when combined with standard of care. Development of Tavocept-specific biomarkers will help predict responders using genetic screening with high confidence while recruiting patients for a precision phase 3 clinical trial.

Background

An Overall Survival (OS) of 25 months, with a 2-year survival of 51.4%, in females with advanced adenocarcinoma of the lung receiving paclitaxel/cisplatin & LP300®
More than 540 Patients treated. Asian study arm responded better than non-Asian arm
Results in non-smoking women were also statistically significant in favor of LP300 for OS (p=0.017) & the 2-year survival was 72% for LP300 vs. 32% for Placebo.

Mechanism of Action

LP-184 is a non-hormone, non-chemotherapy, next-generation DNA Damage Repair (DDR) inhibitor. Indicated primarily in solid tumors such as prostate and ovarian cancers along with renal, lung and brain cancers, LP-184 is a next generation analog of Irofulven. Developed through combinatorial chemistry and screened against conventional therapies both in vitro and in vivo with superior performance, LP-184 cytotoxicity is mediated through the Transcription Coupled Nucleotide Excision Repair (TC-NER) pathway, via alkylation of DNA leading to cell cycle arrest in S phase. Additional cytotoxic effects on tumor include generation of reactive oxygen species, chemical modification of various intracellular proteins, and induction of the MAPK pathway followed by apoptosis.

Background

LP-184, a next generation analog of Irofulven, demonstrating highly improved anti-tumor efficacy, tumor regression in a xenograft model of multidrug resistant cancer, therapeutic index, and bioavailability and clearance.